2m 2m 2m 2m 2m 2m 2m
ARCT THERAP HLDG (ARCT)
NASDAQ
$7.63+$0.03 (+0.39%)
Price as of Jun 03, 2026 7:49 PM EDT- $225.1MMarket Cap
- -41.15%1-Year Change
- BiotechnologyIndustry
ARCT THERAP HLDG (ARCT)
$7.63+$0.03 (+0.39%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 67.2M -55.87% | 152.3M -8.69% | 166.8M -19.03% | 206.0M +1,566.79% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 67.2M -55.87% | 152.3M -8.69% | 166.8M -19.03% | 206.0M +1,566.79% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -112.2M -42.50% | -195.2M +1.57% | -192.1M +30.04% | -147.8M -14.97% | |
Depreciation and Amortization Expense | 3.0M -14.64% | 3.5M +19.85% | 3.0M +93.65% | 1.5M +28.00% | |
Total Operating Expenses | 158.3M -36.17% | 248.0M +1.21% | 245.0M +26.41% | 193.8M -9.94% | |
Operating Profit | -76.3M -20.29% | -95.7M +22.33% | -78.2M -742.24% | 12.2M +106.00% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 10.1M -33.56% | 15.2M -8.41% | 16.6M +4,050.24% | -420,000 -78.14% | |
Income before Taxes | -65.8M -18.73% | -80.9M +190.23% | -27.9M -362.03% | 10.6M +105.25% | |
Income Taxes | 0 +100.00% | -4,000 -100.22% | 1.8M +41.70% | 1.3M N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -65.8M -18.73% | -80.9M +172.30% | -29.7M -417.95% | 9.3M +104.59% | |
Net Income from Continuing Operations Applicable to Common | -65.8M -18.73% | -80.9M +190.23% | -27.9M -362.03% | 10.6M +105.23% | |
Basic EPS and Net Income | -2.40 -20.00% | -3.00 +167.86% | -1.12 -420.00% | 0.35 +104.52% | |
Diluted EPS and Net Income | -2.40 -20.00% | -3.00 +167.86% | -1.12 -420.00% | 0.35 +104.52% | |
Basic Weighted Average Shares | 27.4M +1.43% | 27.0M +1.40% | 26.6M +0.69% | 26.4M +0.49% | |
Diluted Weighted Average Shares | 27.4M +1.43% | 27.0M +1.40% | 26.6M -1.72% | 27.1M +2.95% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 230.9M -2.58% | 237.0M -18.83% | 292.0M -25.49% | 391.9M +5.77% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 230.9M -2.58% | 237.0M -18.83% | 292.0M -25.49% | 391.9M +5.77% | |
Total Current Assets | 241.4M -21.09% | 306.0M -20.85% | 386.6M -4.15% | 403.3M +6.43% | |
Accumulated Depreciation | 12.5M +5.76% | 11.8M +35.14% | 8.7M +51.13% | 5.8M +35.88% | |
Property and Plant and Equipment and Net | 6.7M -29.33% | 9.5M -23.30% | 12.4M +0.10% | 12.4M +120.01% | |
Total Long-Term Assets | 6.7M -29.33% | 9.5M -23.30% | 12.4M +0.10% | 12.4M +120.01% | |
Total Assets | 271.1M -21.19% | 344.1M -19.87% | 429.4M -4.66% | 450.4M +14.66% | |
Income Taxes Payable | N/A N/A | 641,000 0.00% | 641,000 -50.50% | 1.3M N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | 60.7M 0.00% | 60.7M +169.89% | |
Total Current Liabilities | 36.4M -44.45% | 65.5M -20.12% | 82.0M -35.43% | 127.0M +27.57% | |
Total Long-Term Debt | N/A N/A | 0 N/A | 0 -100.00% | 40.6M 0.00% | |
Total Long-Term Liabilities | 33.4M +6,617.91% | 497,000 0.00% | 497,000 -82.28% | 2.8M -95.69% | |
Total Liabilities | 57.2M -44.55% | 103.1M -31.68% | 150.9M -16.21% | 180.1M +9.40% | |
Retained Earnings | -514.6M +14.66% | -448.8M +22.00% | -367.9M +8.79% | -338.1M -2.69% | |
Total Stockholders Equity | 214.0M -11.20% | 241.0M -13.48% | 278.5M +3.03% | 270.3M +18.45% | |
Total Shares Outstanding | 28.4M +5.24% | 27.0M +0.64% | 26.8M +1.03% | 26.6M +0.69% | |
Cash Flow | |||||
Cash from Operating Activities | -74.3M +24.31% | -59.7M +230.11% | -18.1M -156.57% | 32.0M +123.69% | |
Capital Expenditures | 230,000 -64.51% | 648,000 -77.66% | 2.9M -62.45% | 7.7M +126.83% | |
Cash from Investing Activities | -230,000 -64.51% | -648,000 -77.66% | -2.9M -62.45% | -7.7M +126.83% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 13.4M +146.99% | 5.4M +122.49% | -24.1M +742.50% | -2.9M -105.95% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -113.45% +80.61% | -62.81% +33.97% | -46.89% -893.17% | 5.91% +100.36% | |
Return on Assets | -21.39% +2.18% | -20.93% +209.73% | -6.76% -404.73% | 2.22% +104.73% | |
Return on Equity | -28.92% -7.20% | -31.16% +187.68% | -10.83% -388.80% | 3.75% +105.75% | |
Revenue Growth | -55.87% +543.13% | -8.69% -54.35% | -19.03% -101.21% | 1,566.79% +5,199.88% | |
Current Ratio | 6.64 +42.05% | 4.67 -0.91% | 4.72 +48.45% | 3.18 -16.57% | |
Cash Ratio | 6.35 +75.37% | 3.62 +1.63% | 3.56 +15.40% | 3.09 -17.09% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | 0.22 -41.87% | 0.37 +35.52% | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.14 -37.17% | 0.22 +39.95% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow